No Prescription Exists for Methamphetamine Addiction. The FDA Just Took the First Step to Write One.

The morning Marcus walked into his doctor’s office and said he needed help stopping meth, his doctor told him something he was not prepared to hear. Not that it was hard, or that it would take time, or that there were support groups nearby. Those things came later. What came first was simpler: We don’t have a medication for that.

For opioid addiction, there are three FDA-approved medications — methadone, buprenorphine, and naltrexone — with decades of evidence behind them and millions of people alive today because of them. For alcohol addiction, there are three more: naltrexone, acamprosate, and disulfiram. The science on pharmacological treatment for addiction is not new. It is not controversial. It works.

For methamphetamine use disorder, which killed roughly 35,000 Americans in 2023 — approximately one in three of all overdose deaths that year — there is nothing a doctor can prescribe, nothing a pharmacist can dispense, nothing an insurance company is obligated to cover.

The gap in methamphetamine treatment is not a failure of science. It’s a failure of political will to treat this disease like a disease.

The FDA took a small but meaningful step toward correcting this in June 2026, publishing draft guidance specifically aimed at helping pharmaceutical sponsors design clinical trials for stimulant use disorders — the first time the agency has issued such guidance. It did not happen because the science suddenly advanced. It happened because after fifty years of treating meth addiction as a law enforcement problem, the case for a different approach had grown unanswerable.

---

The line the crisis is drawing — and ignoring

The numbers on methamphetamine deaths have been reshaping the overdose picture for years, largely without the attention that fentanyl commands. CDC data show that in 2023, psychostimulants — primarily methamphetamine — were involved in nearly 35,000 overdose deaths, roughly a third of all drug overdose fatalities that year. That figure represents more deaths annually than the entire U.S. overdose toll at the peak of the heroin epidemic in the 1990s.

What makes the methamphetamine crisis distinct is not its scale but its treatment landscape. Someone who walks into an emergency department with an opioid overdose and survives can, in many states, receive a prescription for buprenorphine before they leave the building — a practice that Florida paramedics and ERs pioneered and that evidence shows dramatically cuts re-overdose rates. Someone who walks into an ED with a methamphetamine-involved overdose receives supportive care, maybe a social work referral, and is discharged into a treatment system that has no pharmacological anchor point.

“We’re asking people to do the hardest thing — change a behavior that rewired their brain — without the tools that make it possible,” said a clinician quoted in a 2026 California Health Care Foundation analysis of the treatment gap. “We wouldn’t tell someone with hypertension that they need to try harder. We give them medication. For meth, we’ve never had that.”

Contingency management — a behavioral therapy that works by rewarding drug-free urine samples with small cash payments or gift cards — is the most rigorously tested treatment for methamphetamine use disorder. A meta-analysis in JAMA Psychiatry found that 80 percent of contingency management studies showed the intervention was effective at helping people reduce stimulant use. But contingency management is a behavioral intervention that works best as a complement to a medication — the way CBT works best alongside antidepressants for depression. Without a pharmacological anchor, the evidence on long-term abstinence rates is thin.

And a federal cap of $75 per week on contingency management incentives — a rule rooted in a 1970s statute that treats cash payments as drug paraphernalia in disguise — has limited how programs can implement it at scale.

---

We called it a choice, so we didn’t fund the science

If you were building an addiction research program from scratch and asked where the pharmacological treatment gaps were, you would not arrive at methamphetamine by accident. You would get there by asking why — for four decades — no one was looking.

You would get there by asking why — for four decades — no one was looking.

The answer runs through a specific moment in American history.

In 1986, Congress passed the Anti-Drug Abuse Act — the law that created the 100-to-1 sentencing disparity between crack cocaine and powder cocaine. The law did not just reshape sentencing. It reshaped the entire cultural frame for stimulant addiction. Stimulant use disorder — in Black communities with crack, in rural white communities with meth by the 1990s — became coded as a moral failure, a law enforcement problem, a question of personal responsibility. Not a disease. Not a target for clinical research. The congressional hearings of the 1980s and 1990s were not about finding medications. They were about punishment.

This framing had a direct effect on research investment. NIH’s stimulant research budget went heavily toward imaging studies and animal models that documented the problem — showed addiction reshaping brain structure, documented the dopamine system’s role — without creating the clinical-trial pathways that would produce therapies. The FDA had never issued guidance on how to design a trial for stimulant use disorder because no major pharmaceutical company had made that their business, and without that guidance, the trial design questions were unanswered, and without those answers, the investment stayed out.

The result, in 2026, is a clinical void that every clinician treating meth dependence knows intimately: a comprehensive list of what works, with nothing that can be prescribed.

---

Where the science has been finding pieces of an answer

The absence of an FDA-approved medication does not mean the science has been standing still. It means the findings have been accumulating without a clinical-trial pathway to move them forward — until now.

The most developed candidate is a combination of two existing medications: injectable naltrexone — an opioid antagonist (a drug that blocks opioid receptors in the brain, blunting the reward signal) — plus extended-release oral bupropion, which most people know as Wellbutrin, used for depression and smoking cessation. A NIH-funded trial found that participants receiving both medications had a 27 percent increase in methamphetamine-negative urine tests compared to placebo — a meaningful signal in a field where signals are scarce. Neither medication is approved for methamphetamine use disorder on its own, and the combination requires a physician willing to use them off-label.

A second line of investigation points toward the immune system. A January 2026 University of Florida study discovered a sequence of events in the brain: methamphetamine-induced dopamine spikes — the surge of the brain’s reward chemical that creates the high — trigger tumor necrosis factor-alpha (TNF-alpha), an inflammatory signaling protein your body uses to fight infection and injury. In plain terms: meth use causes a kind of neurological inflammation that seems to drive the craving cycle. The UF researchers suggested this could open the door to testing immune-modulating medicines — drugs already approved for conditions like rheumatoid arthritis and Crohn’s disease — as potential tools to break meth dependency. This is early-stage, animal-model-level evidence. But it is the kind of mechanistic insight that can redirect a field.

---

What the FDA guidance actually does — and doesn’t do

The FDA’s new draft guidance is a clinical trial design document. It tells pharmaceutical sponsors: here is what FDA would want to see in a trial evaluating a therapy for stimulant use disorders. Specifically, it addresses outcomes (what you measure), endpoints (what counts as success), population definitions, and trial duration. This matters because without that guidance, sponsors had to navigate ambiguity that made investment risky.

What the guidance does not do is approve a medication. There is no new pill in the pipeline that will reach a pharmacist’s shelf next year. The guidance creates a clearer pathway for investment — a sign that the FDA is ready to review trials, that it has a framework, that running a stimulant use disorder trial is now a navigable regulatory undertaking rather than an open-ended bet.

There is no new pill in the pipeline that will reach a pharmacist’s shelf next year.

Historically, FDA guidance has been a leading indicator. The agency issued draft guidance for opioid use disorder clinical trials in the early 2010s as part of the regulatory groundwork that eventually gave us extended-release naltrexone (Vivitrol) as a new form of medication for OUD. It issued guidance on alcohol use disorder trials that preceded a wave of investigation into compounds like acamprosate and gabapentin. The pathway-clearing function is real. Whether capital and sponsors follow is a separate question — one that depends partly on whether policymakers pair the guidance with research investment.

---

What you can actually get, today

If you are trying to quit meth right now, the absence of an FDA-approved medication does not mean there is nothing.

Contingency management is real, effective, and available — though you may have to look for it. Treatment programs that offer structured reward-based therapy for stimulant use disorder exist in most states; the challenge is finding them and having an insurance plan that covers them. The SAMHSA treatment locator is one starting point; asking specifically for “contingency management for stimulants” will narrow it quickly.

If your physician is willing to work with you on the naltrexone-bupropion combination off-label, the evidence supports that conversation. This is not standard of care, and most clinicians in primary care settings may not know the NIH trial results. Bringing the NIH study to your appointment is a legitimate clinical conversation.

If you are a provider treating patients with meth use disorder: the gap in your toolkit is not a gap you created. Screening systematically for stimulant use using validated tools — and documenting what you’re seeing — is data that advocates are using to build the case for research investment. Starting patients on contingency management, even in resource-limited settings, and connecting them to clinical trial registries at ClinicalTrials.gov is the current standard of care. It is insufficient. Saying so plainly to your patients, and to your systems, matters.

---

The kicker: a guidance document isn’t a prescription

Marcus’s doctor couldn’t prescribe anything for his meth use disorder. Five years later, Marcus is in sustained recovery. He got there through a combination of contingency management, a strong sponsor in a 12-step program, and a therapist who knew the literature well enough to discuss naltrexone off-label. He will tell you it was the hardest thing he has ever done — harder because there was no medication to help him through the first weeks, when cravings are severe enough to be physically painful and the brain’s reward system has been so thoroughly rewritten by meth that nothing else triggers pleasure.

The FDA guidance issued this month doesn’t change what Marcus had to go through. What it might change, if research funding follows, is what the next person has available when they sit down in that same doctor’s office and say: I need help stopping meth.

The clinical-trial pathway is clearer now. The question is whether anyone runs down it.